2月28日,总部设在新加坡的生物科技公司KBP Biosciences Pte. Ltd. (下称KBP)发表声明,回应新加坡国际商事法院(SICC)近期作出的裁决。SICC于2025年2月14日批准了诺和诺德公司针对KBP及其创始人黄振华博士申请的禁令。KBP表示,SICC的裁决是在公司及创始人黄振华不知情、未参与的情况下,在诺和诺德单方面申请后作出的。诺和诺德曾于2024年6月26日单方...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.